Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2024-04-24 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
董事会审计委员会2023年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board Audit Committee 2023 Annual Performance Report" of a company. It details the audit committee's activities, meetings, oversight of financial reports, internal controls, external audit supervision, and other governance-related functions for the year 2023. It is a report on the audit committee's duties and performance rather than a standalone audit report or full annual report. The document length is 3678 characters, which is relatively short and focused on committee activities and oversight rather than full financial statements or audit opinions. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and related committee reports on audit and internal controls, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-24 Chinese
关于注销2021年股票期权激励计划部分已授予股票期权的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of part of its 2021 stock option incentive plan. It details board and supervisory meetings, legal opinions, and specific numbers of stock options to be cancelled due to various reasons such as employee departure and unmet performance conditions. The document does not contain financial statements or quarterly/yearly financial results but focuses on corporate governance and share-based compensation matters. This fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement about stock option cancellations and related corporate actions, not a full financial report or earnings release.
2024-04-24 Chinese
监事会关于2021年股票期权激励计划第二个行权期可行权激励对象名单的审核意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the verification of the list of eligible stock option incentive recipients for the second exercise period of the 2021 stock option incentive plan. It references compliance with company law, stock exchange listing rules, and internal company regulations. The content focuses on the verification and approval of stock option exercise conditions and eligible participants. It is not a full financial report, earnings release, or management discussion. It is also not an announcement of voting results or a proxy statement. The document is a formal supervisory board statement related to stock option incentive plan compliance and exercise approval, which fits best under Regulatory Filings (RNS) as it is a compliance and regulatory-related announcement rather than a financial report or capital change announcement. The document length is short (1172 characters), and it is a formal opinion rather than a report or announcement of a report publication.
2024-04-24 Chinese
关于召开2023年度暨2024年第一季度业绩说明会的公告
Call Transcript Classification · 95% confidence The document is an announcement about the scheduling and details of an upcoming earnings explanation meeting (业绩说明会) for the 2023 annual and 2024 first quarter results. It provides the meeting time, location, participation method, and contact information. It references that the 2023 annual report and 2024 Q1 report have or will be disclosed separately. The document does not contain actual financial data or detailed financial statements but is an invitation and information notice about the earnings call event. Therefore, it is classified as a Call Transcript (CT) type document, specifically an announcement of an earnings explanation meeting, which aligns with the Call Transcript category rather than the Earnings Release or Interim Report categories, as it is about the call itself and interaction with investors.
2024-04-24 Chinese
海通证券股份有限公司关于和元生物技术（上海）股份有限公司2023年度募集资金存放与实际使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the 2023 annual verification of the deposit and actual use of funds raised by Heyuan Biotechnology (Shanghai) Co., Ltd. It includes specific financial figures about the amount raised, usage, balances, and compliance with regulatory requirements. The document references regulatory guidelines related to the management and use of raised funds, includes a verification opinion from an accounting firm, and a sponsor's verification opinion. The content focuses on the management and use of funds raised in an IPO context for the year 2023, with detailed tables and explanations. This matches the characteristics of an Audit Report / Information (AR) as it is a standalone report on the audit and verification of the use of raised funds, not a full annual report or earnings release. The document length (7,672 characters) and detailed financial data confirm it is a substantive report, not merely an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-24 Chinese
《2023年度独立董事述职报告》（GANG WANG）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's background, attendance at board and committee meetings, oversight activities, and governance-related matters during the 2023 fiscal year. The content focuses on the independent director's duties, governance, and compliance with laws and company rules. It does not contain financial statements or quarterly/annual financial results, nor is it an announcement or proxy solicitation. It is a management-related report focusing on board and governance activities, which fits best under Board/Management Information (MANG).
2024-04-24 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.